XENON PHARMACEUTICALS INC. Contract Liability (Deferred Revenue)
XENON PHARMACEUTICALS INC. (XENE) had Contract Liability (Deferred Revenue) of $2.20 million as of 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2022-03-01
- 2021-09-30: Contract with Customer, Liability, Current $2.20M.
- 2021-06-30: Contract with Customer, Liability, Current $3.02M.
- 2021-03-31: Contract with Customer, Liability, Current $3.64M.
- 2020-12-31: Contract with Customer, Liability, Current $3.64M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2021-09-30 | $2.20M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $3.02M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $3.64M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $3.64M 10-K · filed 2022-03-01 |
| 2020-09-30 | $7.45M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $12.69M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $24.61M 10-Q/A · filed 2020-05-26 |
| 2019-12-31 | $29.74M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |